Search: WFRF:(Subira Dolores) >
Monitoring treatmen...
Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome
-
- Subirá, Dolores (author)
- Hospital Universitario de Guadalajara
-
- Alhan, Canan (author)
- Amsterdam UMC - Vrije Universiteit Amsterdam
-
- Oelschlaegel, Uta (author)
- Medizinsche Klinik und Poliklinik I, Dresden
-
show more...
-
- Porwit, Anna (author)
- Lund University,Lunds universitet,Patologi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Pathology, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine
-
- Psarra, Katherina (author)
- Evangelismos Athens General Hospital
-
- Westers, Theresia M. (author)
- Amsterdam UMC - Vrije Universiteit Amsterdam
-
- Golbano, Nuria (author)
- Hospital Universitario de Guadalajara
-
- Nilsson, Lars (author)
- Skåne University Hospital
-
- van de Loosdrecht, Arjan A. (author)
- Amsterdam UMC - Vrije Universiteit Amsterdam
-
- de Miguel, Dunia (author)
- Hospital Universitario de Guadalajara
-
show less...
-
(creator_code:org_t)
- 2021-01-09
- 2021
- English 12 s.
-
In: Annals of Hematology. - : Springer Science and Business Media LLC. - 0939-5555 .- 1432-0584. ; 100:7, s. 1711-1722
- Related links:
-
http://dx.doi.org/10...
-
show more...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- 5-Azacitidine (AZA) therapy is used in high-risk myelodysplastic syndrome (MDS) patients who often show abnormalities in their immunophenotype. We explored the potential impact of AZA on these immunophenotypic abnormalities in serial bone marrow studies performed in 81 patients from five centers. We compared the immunophenotypic features before and after therapy with AZA, established definitions consistent with flow cytometry immunophenotyping (FCI) improvement, and explored its clinical significance. After a median of 6 cycles of AZA, 41% of patients showed a FCI improvement and this finding associated with best possible clinical response (P < 0.001). FCI improvement also correlated with hematological improvement (HI) (53/78 patients; 68%), independently of their eligibility for stem cell transplantation. Among patients who achieved a HI after 6 cycles of AZA, the probability of maintaining this response at 12 cycles of AZA was twice as large (67%) for those patients who also achieved a FCI improvement after 6 cycles of AZA as compared to patients who did not (33%, P < 0.01). These findings support that monitoring of the immunophenotypic abnormalities during therapy with AZA may assist in redefining the quality of response in patients with MDS.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Keyword
- 5-Azacitidine response
- Flow cytometry
- Immunophenotype
- MDS
- Myelodysplastic syndrome
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database